JP6116246B2 - イオントフォレシスにより悪心および片頭痛を治療するための方法 - Google Patents

イオントフォレシスにより悪心および片頭痛を治療するための方法 Download PDF

Info

Publication number
JP6116246B2
JP6116246B2 JP2012524789A JP2012524789A JP6116246B2 JP 6116246 B2 JP6116246 B2 JP 6116246B2 JP 2012524789 A JP2012524789 A JP 2012524789A JP 2012524789 A JP2012524789 A JP 2012524789A JP 6116246 B2 JP6116246 B2 JP 6116246B2
Authority
JP
Japan
Prior art keywords
migraine
delivery device
subject
drug delivery
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012524789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501796A5 (enExample
JP2013501796A (ja
Inventor
セブリー，テリ，ビー．
ピアース，マーク
オニール，キャロル
Original Assignee
テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー filed Critical テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー
Publication of JP2013501796A publication Critical patent/JP2013501796A/ja
Publication of JP2013501796A5 publication Critical patent/JP2013501796A5/ja
Application granted granted Critical
Publication of JP6116246B2 publication Critical patent/JP6116246B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012524789A 2009-08-10 2010-08-10 イオントフォレシスにより悪心および片頭痛を治療するための方法 Active JP6116246B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23261709P 2009-08-10 2009-08-10
US61/232,617 2009-08-10
US25679609P 2009-10-30 2009-10-30
US61/256,796 2009-10-30
US35830010P 2010-06-24 2010-06-24
US61/358,300 2010-06-24
PCT/US2010/045045 WO2011019732A1 (en) 2009-08-10 2010-08-10 Methods for iontophoretically treating nausea and migraine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015150968A Division JP2016014028A (ja) 2009-08-10 2015-07-30 イオントフォレシスにより悪心および片頭痛を治療するための方法

Publications (3)

Publication Number Publication Date
JP2013501796A JP2013501796A (ja) 2013-01-17
JP2013501796A5 JP2013501796A5 (enExample) 2013-09-19
JP6116246B2 true JP6116246B2 (ja) 2017-04-19

Family

ID=43586432

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012524789A Active JP6116246B2 (ja) 2009-08-10 2010-08-10 イオントフォレシスにより悪心および片頭痛を治療するための方法
JP2015150968A Pending JP2016014028A (ja) 2009-08-10 2015-07-30 イオントフォレシスにより悪心および片頭痛を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015150968A Pending JP2016014028A (ja) 2009-08-10 2015-07-30 イオントフォレシスにより悪心および片頭痛を治療するための方法

Country Status (11)

Country Link
US (2) US8845612B2 (enExample)
EP (1) EP2464234A4 (enExample)
JP (2) JP6116246B2 (enExample)
CN (3) CN105748401A (enExample)
AU (1) AU2010282660B2 (enExample)
BR (1) BR112012003111A8 (enExample)
CA (1) CA2770211A1 (enExample)
EA (1) EA201270227A1 (enExample)
IL (1) IL217935A0 (enExample)
NZ (1) NZ598622A (enExample)
WO (1) WO2011019732A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
BR112012003111A8 (pt) 2009-08-10 2017-10-10 Nupathe Inc Métodos para tratar iontoforeticamente náusea e enxaqueca
EP3416618A1 (en) 2016-02-19 2018-12-26 ZP Opco, Inc. Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US11660264B2 (en) 2017-08-23 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
US11660265B2 (en) 2018-06-28 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4856188A (en) * 1984-10-12 1989-08-15 Drug Delivery Systems Inc. Method for making disposable and/or replenishable transdermal drug applicators
US5605536A (en) * 1983-08-18 1997-02-25 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
US5651768A (en) * 1983-08-18 1997-07-29 Drug Delivery Systems, Inc. Transdermal drug applicator and electrodes therefor
US4822802A (en) * 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
US5207752A (en) * 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
DE4014913C2 (de) * 1990-05-10 1996-05-15 Lohmann Therapie Syst Lts Miniaturisiertes transdermales therapeutisches System für die Iontophorese
JP3488466B2 (ja) * 1992-06-02 2004-01-19 アルザ・コーポレーション 電気駆動式薬物投与デバイス
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5458569A (en) * 1993-06-08 1995-10-17 Becton Dickinson And Company Wearable iontophoresis system
US5533971A (en) * 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
DE69429603T2 (de) * 1993-09-22 2002-08-14 Hisamitsu Pharmaceutical Co., Inc. Iontophoresematrix
US5697896A (en) 1994-12-08 1997-12-16 Alza Corporation Electrotransport delivery device
IE960312A1 (en) * 1995-06-02 1996-12-11 Alza Corp An electrotransport delivery device with voltage boosting¹circuit
US6216033B1 (en) * 1996-05-22 2001-04-10 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6425892B2 (en) * 1995-06-05 2002-07-30 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
AU699774B2 (en) * 1995-06-05 1998-12-17 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6245347B1 (en) * 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5941843A (en) * 1996-07-12 1999-08-24 Empi, Inc. Iontophoresis electrode
US5882677A (en) * 1997-09-30 1999-03-16 Becton Dickinson And Company Iontophoretic patch with hydrogel reservoir
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
US6421561B1 (en) * 1999-12-30 2002-07-16 Birch Point Medical, Inc. Rate adjustable drug delivery system
IT1319210B1 (it) * 2000-10-13 2003-09-26 Italiano Biochimico Lisapharma Pellicola per la somministrazione dermica e transdermica di principiattivi.
US6653014B2 (en) * 2001-05-30 2003-11-25 Birch Point Medical, Inc. Power sources for iontophoretic drug delivery systems
EP1435945B1 (en) * 2001-06-05 2008-08-13 Aung-din, Ronald Topical migraine therapy
CA2512854C (en) * 2002-06-28 2010-02-09 Alza Corporation A reservoir for use in electrotransport drug delivery
US6745071B1 (en) * 2003-02-21 2004-06-01 Birch Point Medical, Inc. Iontophoretic drug delivery system
RU2326893C2 (ru) * 2003-04-16 2008-06-20 Кориум Интернэшнл Ковалентное и нековалентное сшивание гидрофильных полимеров и адгезивные композиции, полученные с ними
US8734421B2 (en) * 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
US20050228336A1 (en) * 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
US7856263B2 (en) * 2005-04-22 2010-12-21 Travanti Pharma Inc. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
JP2009509685A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 損傷組織の治癒を増強するための血管新生因子の送達のためのイオントフォレーシス装置及び方法
US20070093788A1 (en) * 2005-09-30 2007-04-26 Darrick Carter Iontophoresis method and apparatus for systemic delivery of active agents
CA2935569A1 (en) * 2006-04-13 2007-10-25 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
US8155737B2 (en) 2008-06-19 2012-04-10 Nupathe, Inc. Pharmacokinetics of iontophoretic sumatriptan administration
BR112012003111A8 (pt) 2009-08-10 2017-10-10 Nupathe Inc Métodos para tratar iontoforeticamente náusea e enxaqueca

Also Published As

Publication number Publication date
CN102573489A (zh) 2012-07-11
US20150032083A1 (en) 2015-01-29
WO2011019732A1 (en) 2011-02-17
AU2010282660A1 (en) 2012-03-08
US20110066100A1 (en) 2011-03-17
JP2013501796A (ja) 2013-01-17
US8845612B2 (en) 2014-09-30
CN105796533A (zh) 2016-07-27
NZ598622A (en) 2014-02-28
AU2010282660B2 (en) 2015-06-25
EP2464234A4 (en) 2013-01-02
EA201270227A1 (ru) 2012-10-30
BR112012003111A8 (pt) 2017-10-10
CA2770211A1 (en) 2011-02-17
EP2464234A1 (en) 2012-06-20
BR112012003111A2 (pt) 2015-10-13
CN105748401A (zh) 2016-07-13
US9592291B2 (en) 2017-03-14
JP2016014028A (ja) 2016-01-28
IL217935A0 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
JP6116246B2 (ja) イオントフォレシスにより悪心および片頭痛を治療するための方法
JP5580042B2 (ja) 抗片頭痛化合物の送達のための経皮的方法およびシステム
JP6768733B2 (ja) モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
CN101754756A (zh) 包含磷酸二酯酶-5抑制剂的新组合和它们的用途
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JP5951741B2 (ja) イオントフォレシスによるスマトリプタン投与の薬物動態
NO309965B1 (no) Oralt farmasøytisk antihostepreparat
US7026319B1 (en) Use of vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation
WO1999032103A1 (en) New use of local anaesthetics against vascular headaches
Zimmer et al. Noninvasive drug delivery
AU2015230711A1 (en) Methods for iontophoretically treating nausea and migraine
KR20030022352A (ko) 일차성 두통의 치료에서 비타민 혼합물의 용도
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150331

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150730

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151016

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170321

R150 Certificate of patent or registration of utility model

Ref document number: 6116246

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150